CVE:MDP - Pediapharm Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pediapharm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$4.00 +0.20 (+5.26 %) (As of 02/28/2020 04:00 PM ET) Add Compare Today's RangeC$3.51Now: C$4.00▼C$4.0050-Day RangeC$3.32MA: C$3.66▼C$4.0552-Week RangeC$3.25Now: C$4.00▼C$5.00Volume22,600 shsAverage Volume8,054 shsMarket CapitalizationC$56.23 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2003 and is headquartered in Verdun, Canada. Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:MDP Previous Symbol CUSIPN/A CIKN/A Webhttp://www.medexus.com/ Phone514-762-2626Debt Debt-to-Equity Ratio87.84 Current Ratio2.10 Quick Ratio1.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth658.5 Sales & Book Value Annual SalesC$61.47 million Price / Sales0.91 Cash FlowC$1.75 per share Price / Cash Flow2.28 Book ValueC$2.13 per share Price / Book1.87Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares14,058,000Market CapC$56.23 million Next Earnings Date7/13/2020 (Estimated) OptionableOptionable Receive MDP News and Ratings via Email Sign-up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. TSXV:MDP Rates by TradingView Pediapharm (CVE:MDP) Frequently Asked Questions What is Pediapharm's stock symbol? Pediapharm trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP." When is Pediapharm's next earnings date? Pediapharm is scheduled to release their next quarterly earnings announcement on Monday, July 13th 2020. View Earnings Estimates for Pediapharm. What price target have analysts set for MDP? 2 Wall Street analysts have issued 12 month price targets for Pediapharm's shares. Their forecasts range from C$6.50 to C$6.50. On average, they expect Pediapharm's share price to reach C$6.50 in the next twelve months. This suggests a possible upside of 62.5% from the stock's current price. View Analyst Price Targets for Pediapharm. What is the consensus analysts' recommendation for Pediapharm? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pediapharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pediapharm. Has Pediapharm been receiving favorable news coverage? News headlines about MDP stock have trended very negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pediapharm earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Pediapharm. Who are some of Pediapharm's key competitors? Some companies that are related to Pediapharm include Amryt Pharma (AMYT), Shield Therapeutics (STX), Probiotec (PBP), ESSA Pharma (EPI), Green Organic Dutchman (TGOD), CannTrust (TRST), Auscann Group (AC8), Supreme Cannabis (FIRE), WeedMD (WMD), Delta 9 Cannabis (NINE), Depomed (ASRT), Flowr (FLWR), Biosyent (RX), Althea Group (AGH) and Science in Sport (SIS). What other stocks do shareholders of Pediapharm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pediapharm investors own include Enghouse Systems (ENGH), Ag Growth International (AFN), Gatekeeper Systems (GSI) and Antibe Therapeutics (ATE). Who are Pediapharm's key executives? Pediapharm's management team includes the folowing people: Mr. Sylvain Chretien, Pres & Director (Age 55)Mr. Roland Boivin, Chief Financial OfficerMr. Richard Labelle, VP of Sales & MarketingMr. Benoît Hébert, VP of Bus. Devel. & Licensing (Age 51)Mr. Normand Chartrand, Consultant (Age 60) How do I buy shares of Pediapharm? Shares of MDP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Pediapharm's stock price today? One share of MDP stock can currently be purchased for approximately C$4.00. How big of a company is Pediapharm? Pediapharm has a market capitalization of C$56.23 million and generates C$61.47 million in revenue each year. View Additional Information About Pediapharm. What is Pediapharm's official website? The official website for Pediapharm is http://www.medexus.com/. How can I contact Pediapharm? The company can be reached via phone at 514-762-2626. MarketBeat Community Rating for Pediapharm (CVE MDP)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 15 (Vote Outperform)Underperform Votes: 9 (Vote Underperform)Total Votes: 24MarketBeat's community ratings are surveys of what our community members think about Pediapharm and other stocks. Vote "Outperform" if you believe MDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/29/2020 by MarketBeat.com StaffFeatured Article: What is Green Investing?
